Valuation : Artiva Biotherapeutics, Inc.

Market Cap 547M 470M 443M 404M 755M 51.74B 758M 5.25B 2.03B 26.5B 2.05B 2.01B 84.4B P/E 2026 *
-4.31x
P/E 2027 * -4.14x
Enterprise Value 547M 470M 443M 404M 755M 51.74B 758M 5.25B 2.03B 26.5B 2.05B 2.01B 84.4B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
85.12%
Yield 2026 *
-
Yield 2027 * -
1 day-1.61%
1 week-2.39%
Current month-2.57%
1 month-1.87%
3 months+61.91%
6 months+92.82%
Current year+156.64%
1 week 10.7
Extreme 10.7
11.51
1 month 10.49
Extreme 10.49
12.27
Current year 3.62
Extreme 3.62
14.53
1 year 2.22
Extreme 2.22
14.53
3 years 1.47
Extreme 1.47
17.31
5 years 1.47
Extreme 1.47
17.31
10 years 1.47
Extreme 1.47
17.31
Manager TitleAgeSince
Chief Executive Officer 51 2021-01-04
President 63 2026-05-17
Chief Tech/Sci/R&D Officer - 2026-04-30
Director TitleAgeSince
Director/Board Member 40 2020-05-31
Director/Board Member 51 2021-01-04
Chairman 67 2020-05-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/3/26 Sell

Chief Technology Officer

-10,366 0.0425%
9/3/26 Sell

Compliance Officer

-8,391 0.0344%
9/3/26 Sell

Chief Technology Officer

-1,100 0.0045%
Change 5-day change 1-year change 3-year change Capi.($)
-1.61%-2.39%+256.31% - 547M
-0.82%-3.77%-2.49%+14.92% 48.41B
+0.71%+0.81%+415.27%+558.69% 45.01B
-1.77%+1.52%+39.74%+22.83% 44.07B
-2.85%-2.49%+0.95%+81.56% 40.73B
-1.72%-3.07%+13.76%+43.40% 33.21B
-0.07%+3.05% - - 17.77B
-0.01%+0.92%+19.61%+117.10% 16.5B
-0.56%-0.50%+11.39%+31.41% 14.45B
-1.66%+0.02%+74.33%+41.39% 13.77B
Average -0.97%+0.27%+92.10%+113.91% 27.45B
Weighted average by Cap. -0.96%-0.12%+87.54%+135.06%

Financials

2026 *2027 *
Net sales - -
Net income -107M -92.01M -86.54M -79M -148M -10.12B -148M -1.03B -397M -5.18B -402M -393M -16.51B -135M -116M -109M -99.88M -187M -12.79B -187M -1.3B -501M -6.55B -508M -497M -20.87B
Net Debt - -
Logo Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Its product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as systemic lupus erythematosus (SLE), lupus nephritis (LN), RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in SLE with or without LN and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.
Employees
115
Date Price Change Volume
26-09-08 US$11.01 -1.61% 79,417
26-09-04 US$11.19 +0.58% 168,592
26-09-03 US$11.13 -1.64% 365,624
26-09-02 US$11.31 +0.27% 306,518
26-09-01 US$11.28 -0.18% 268,855
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
11.19USD
Average target price
35.80USD
Spread / Average Target
+219.93%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ARTV Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!